Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-07

Clinical Trial Update: Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and tolerability of preservative-free 0.0015% tafluprost in primary open-angle glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tafluprost (tafluprost)

Snippet

Sponsor: Gangnam Severance Hospital | Conditions: Primary Open-angle Glaucoma | Phase 4 | Status: COMPLETED